ResearcherUniversity Hospital HeidelbergActive in the last 2 years
Jingyu An
Matched on ORCID iD 0000-0002-3274-3306; OpenAlex author ID A5100526919. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 23
2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 1 paper
Papers 4
- Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures of therapeutic response. Co-author DOI 10.1016/j.tranon.2024.102109↗
- Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. First author DOI 10.1038/s43018-023-00628-6↗
- Corrigendum: Clinical impact of molecular subtyping of pancreatic cancer. Co-author DOI 10.3389/fcell.2023.1179559↗
- Clinical Impact of Molecular Subtyping of Pancreatic Cancer. Co-author DOI 10.3389/fcell.2021.743908↗
Closest collaborators
The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Peter J. Bailey · 4 shared papers, 2021–2024 · strength 0.54
- Paper Corrigendum: Clinical impact of molecular subtyping of pancreatic cancer. DOI 10.3389/fcell.2023.1179559↗
- Paper Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures o… DOI 10.1016/j.tranon.2024.102109↗
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6↗
- Thilo Hackert · 4 shared papers, 2021–2024 · strength 0.54
- Paper Corrigendum: Clinical impact of molecular subtyping of pancreatic cancer. DOI 10.3389/fcell.2023.1179559↗
- Paper Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures o… DOI 10.1016/j.tranon.2024.102109↗
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6↗
- Christoph Springfeld · 4 shared papers, 2021–2024 · strength 0.54
- Paper Corrigendum: Clinical impact of molecular subtyping of pancreatic cancer. DOI 10.3389/fcell.2023.1179559↗
- Paper Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures o… DOI 10.1016/j.tranon.2024.102109↗
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6↗
- Xu Zhou · 4 shared papers, 2021–2024 · strength 0.54
- Paper Corrigendum: Clinical impact of molecular subtyping of pancreatic cancer. DOI 10.3389/fcell.2023.1179559↗
- Paper Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures o… DOI 10.1016/j.tranon.2024.102109↗
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6↗
- John P. Neoptolemos · 4 shared papers, 2021–2024 · strength 0.54
- Paper Corrigendum: Clinical impact of molecular subtyping of pancreatic cancer. DOI 10.3389/fcell.2023.1179559↗
- Paper Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures o… DOI 10.1016/j.tranon.2024.102109↗
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6↗
- Susanne Roth · 3 shared papers, 2021–2024 · strength 0.41
- Paper Corrigendum: Clinical impact of molecular subtyping of pancreatic cancer. DOI 10.3389/fcell.2023.1179559↗
- Paper Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures o… DOI 10.1016/j.tranon.2024.102109↗
- Paper Clinical Impact of Molecular Subtyping of Pancreatic Cancer. DOI 10.3389/fcell.2021.743908↗
- Markus Wolfgang Büchler · 3 shared papers, 2021–2023 · strength 0.39
- Paper Corrigendum: Clinical impact of molecular subtyping of pancreatic cancer. DOI 10.3389/fcell.2023.1179559↗
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6↗
- Paper Clinical Impact of Molecular Subtyping of Pancreatic Cancer. DOI 10.3389/fcell.2021.743908↗
- Shigenori Ei · 2 shared papers, 2023–2024 · strength 0.27
- Paper Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures o… DOI 10.1016/j.tranon.2024.102109↗
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6↗
- Franco Fortunato · 2 shared papers, 2023–2024 · strength 0.27
- Paper Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures o… DOI 10.1016/j.tranon.2024.102109↗
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6↗
- Kongyuan Wei · 2 shared papers, 2021–2023 · strength 0.26
- Malte Buchholz · 2 shared papers, 2021–2023 · strength 0.26
- Thomas Mathias Gress · 2 shared papers, 2021–2023 · strength 0.26
- Martin Loos · 1 shared paper, 2024 · strength 0.14
- Georg Beyer · 1 shared paper, 2024 · strength 0.14
- Julia V. Mayerle · 1 shared paper, 2024 · strength 0.14
- Stephen Jacob Pandol · 1 shared paper, 2024 · strength 0.14
- Christoph W. Michalski · 1 shared paper, 2024 · strength 0.14
- Mouad Edderkaoui · 1 shared paper, 2024 · strength 0.14
- Nicolas Hohmann · 1 shared paper, 2023 · strength 0.13
- Simon T. Barry · 1 shared paper, 2023 · strength 0.13
- Dirk Theile · 1 shared paper, 2023 · strength 0.13
- Oliver Strobel · 1 shared paper, 2023 · strength 0.13
- Ulrike Heger · 1 shared paper, 2023 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.